抑胃多肽受体蛋白表达在阑尾神经内分泌肿瘤患者预后评估中的价值

study on the gastric inhibitory polypeptide receptor protein expression in A-NETs patients

目的探讨抑胃多肽受体（gastric inhibitory polypeptide receptor，GIPR）蛋白在阑尾神经内分泌肿瘤患者预后评估中的价值。方法回顾性分析2007年6月至2017年6月天津市公安医院收治的40例阑尾神经内分泌肿瘤患者的临床病理资料，采用免疫组织化学方法检测阑尾神经内分泌肿瘤组织中GIPR蛋白表达情况。结果40例阑尾神经内分泌肿瘤患者GIPR蛋白表达阳性18例，阴性22例：免疫组化分级G116例，G220例，G34例。患者的性别、肿瘤部位、肿瘤大小、肿瘤分期、淋巴结转移与预后均无关（均P〉0．05）；GIPR蛋白表达和肿瘤分级与患者的预后均有关（均P〈0．05）。结论阑尾神经内分泌肿瘤患者的临床表现无特异性，确诊依赖于病理学和免疫组化检查．GIPR蛋白阳性表达患者较阴性表达患者的预后差。

Objective To evaluate GIPR protein expression in predicting prognosis of appendical neuroendocrine tmnors （ A-NET ） patients. Methods The clinical data of 40 A-NET cases surgically treated from June 2007 to June 2017 at Tianjin Police Hospital were analyzed. The expression of GIPR markers was detected by immnnohistochemistry （IHC）. Results There were 25 male and 15 female patients, with an median age of 59 years. Sex, tumor site, tumor size, tumor stage and lymph node metastasis were not related to prognosis （ P 〉 0. 05）. The expression of GIPR was positive in 18 cases and negative in 22 cases. There were 16 cases in GI stage, 20 cases in G2, 4 cases in G3. The expression of GIPR protein and pathological grades were related to prognosis （ P 〈 0. 05 ）. Conclusions Symptoms of appendix neuroendocrine tumor are nonspecific. Diagnosis is dependent on pathological examination and immunohistochemistry. Positive GIPR protein expression predicts poor prognosis for A-NETs patients.